Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 26

Sort by

Sort Order Select

Journal Articles

Pediatric Patients with Relapsed/Refractory Acute Lymphoblastic Leukemia Harboring Heterogeneous Genomic Profiles Respond to Venetoclax in Combination with Chemotherapy

Andrew E. Place, MDPhD, Seth E. Karol, MD, Christopher J. Forlenza, MD, Marion Gambart, MD, Todd M. Cooper, DO, Christopher Fraser, MBBS, Gunnar Cario, MD PhD, Maureen M O'Brien, MD, Nicolas U. Gerber, MD, Phillip Barnette, MD, Dirk Reinhardt, MDPhD, Giridharan Ramsingh, MD, Bo Tong, PhD, Kristina Unnebrink, PhD, Deeksha Vishwamitra, PhD, Fengjiao Dunbar, PhD, Betty A. Prine, BS, Tammy L. Palenski, PhD, Mignon L. Loh, MD

Blood (2020) 136 (Supplement 1): 37–38.

https://doi.org/10.1182/blood-2020-137376

Published: 2020

Journal Articles

CPX-351 Population Pharmacokinetics in Pediatric and Adult Patients with Acute Myeloid Leukemia (AML)

Qi Wang, Todd M. Cooper, DO, Michael J. Absalon, E. Anders Kolb, MD, Grygoriy Vasilinin, Nathalie H. Gosselin, Todd A. Alonzo, PhD, J.F. Marier

Blood (2020) 136 (Supplement 1): 1.

https://doi.org/10.1182/blood-2020-137163

Published: 2020

Journal Articles

CPX-351 Exposure-Response Analyses for Efficacy and Safety in Pediatric Patients with Relapsed or Refractory Acute Myeloid Leukemia (AML)

Qi Wang, Nathalie H. Gosselin, Michael J. Absalon, E. Anders Kolb, MD, J.F. Marier, Todd A. Alonzo, PhD, Stefan Faderl, Todd M. Cooper, DO

Blood (2020) 136 (Supplement 1): 3.

https://doi.org/10.1182/blood-2020-137205

Published: 2020

Journal Articles

Venetoclax Crosses the Blood Brain Barrier: A Pharmacokinetic Analysis of the Cerebrospinal Fluid in Pediatric Leukemia Patients

Ahmed Hamed Salem, PhD FCP, Mohamed A Badawi, PhD, Andrew E. Place, MDPhD, Tammy L. Palenski, PhD, Richard Arrendale, PhD, Su Young Kim, Sara Federico, MD, Todd M. Cooper, DO, Rajeev Menon, PhD

Blood (2020) 136 (Supplement 1): 30–31.

https://doi.org/10.1182/blood-2020-137197

Published: 2020

Journal Articles

Integrated Stem Cell Signature and Cytomolecular Risk Determination in Pediatric Acute Myeloid Leukemia

Benjamin J. Huang, MD, Jenny L. Smith, MSc, MD, Rhonda E. Ries, MA, Amanda R. Leonti, MS, Erin Lynn Crowgey, PhD, Scott N. Furlan, MD, Timothy Shaw, PhD, Lisa Wei, BS, Yi-Cheng Wang, MS, Robert B. Gerbing, MA, Todd A. Alonzo, PhD, Todd M. Cooper, DO, Edward A. Kolb, MD, Xiaotu Ma, PhD, Jason E. Farrar, MD, Timothy Junius Triche, Jr., PhD, Soheil Meshinchi, MDPhD

Blood (2020) 136 (Supplement 1): 28–29.

https://doi.org/10.1182/blood-2020-142638

Published: 2020

Journal Articles

Venetoclax Alone or in Combination with Chemotherapy: Responses in Pediatric Patients with Relapsed/Refractory Acute Myeloid Leukemia with Heterogeneous Genomic Profiles

Seth E. Karol, MD, Henrique Bittencourt, MD PhD, Daniel A. Morgenstern, MD, Margaret E. Macy, MD, Seong Lin Khaw, MD, Todd M. Cooper, DO, Arnaud Petit, MD PhD, Giridharan Ramsingh, MD, Bo Tong, PhD, Kristina Unnebrink, PhD, Deeksha Vishwamitra, PhD, Fengjiao Dunbar, PhD, Betty A. Prine, BS, Tammy L. Palenski, PhD, Andrew E. Place, MDPhD

Blood (2020) 136 (Supplement 1): 30–31.

https://doi.org/10.1182/blood-2020-136999

Published: 2020

Journal Articles

The Molecular Characteristics and Clinical Relevance of NUP98 -Other Translocations in Pediatric Acute Myeloid Leukemia

Eline J.M. Bertrums, Jenny L. Smith, MSc, MD, Rhonda E. Ries, MA, Todd A. Alonzo, PhD, Fabiana Ostronoff, MD, Gertjan J.L. Kaspers, Prof. MD PhD, Henrik Hasle, PhD, Christian M. Zwaan, Betsy A Hirsch, PhD, Susana C. Raimondi, PhD, Todd M. Cooper, DO, Richard Aplenc, MD PhD, Alan S. Gamis, MD MPH, Edward A. Kolb, MD, Bianca F. Goemans, MD PhD, Soheil Meshinchi, MDPhD

Blood (2020) 136 (Supplement 1): 36–37.

https://doi.org/10.1182/blood-2020-137537

Published: 2020

Journal Articles

Characteristics and Prognostic Effects of IDH Mutations across the Age Spectrum in AML: A Collaborative Analysis from COG, SWOG, and ECOG

Blood (2020) 136 (Supplement 1): 31–32.

https://doi.org/10.1182/blood-2020-134211

Published: 2020

Journal Articles

Newly Diagnosed Childhood AML Patients Treated with Bortezomib Show Superior Survival If CD74 Is Expressed: A Report of 991 Patients from the Children's Oncology Group AAML1031 Protocol

Lisa Eidenschink Brodersen, PhD, Chad A. Hudson, MDPhD, Todd A. Alonzo, PhD, Robert B. Gerbing, MA, Laura Pardo, Amanda R. Leonti, MS, Timothy P. Singleton, MD, Fan-Chi Hsu, PhD, Loren L. Lott, Fangyan Dai, Keely Ghiradelli, E. Anders Kolb, MD, Todd M. Cooper, DO, Jessica A. Pollard, MD, Michael R. Loken, PhD, Richard Aplenc, MD PhD, Soheil Meshinchi, MDPhD

Blood (2020) 136 (Supplement 1): 39.

https://doi.org/10.1182/blood-2020-142659

Published: 2020

Journal Articles

Structural Variants Involving MLLT10/AF10 Are Associated with Adverse Outcome in AML Regardless of the Partner Gene - a COG/Tpaml Study

Rhonda E. Ries, MA, Amanda R. Leonti, MS, Timothy Junius Triche, Jr., PhD, Robert B. Gerbing, Betsy A Hirsch, PhD, Susana C. Raimondi, PhD, Jenny L. Smith, MSc, MD, Todd M Cooper, DO, Jason E. Farrar, MD, Aniruddha J. Deshpande, E. Anders Kolb, MD, Alan S Gamis, MD MPH, Richard Aplenc, MD PhD, Todd A. Alonzo, PhD, Soheil Meshinchi, MD PhD

Blood (2019) 134 (Supplement_1): 461.

https://doi.org/10.1182/blood-2019-125943

Published: 2019

Journal Articles

Correlation of CD123 Expression Level with Disease Characteristics and Outcomes in Pediatric Acute Myeloid Leukemia: A Report from the Children's Oncology Group

Adam J. Lamble, MD, Lisa Eidenschink Brodersen, PhD, Todd A. Alonzo, PhD, Jim Wang, Robert B. Gerbing, Laura Pardo, Lillian Sung, MD PhD, Sarah K. Tasian, MD, Todd M Cooper, DO, E. Anders Kolb, MD, Richard Aplenc, MD PhD, Michael R. Loken, PhD, Soheil Meshinchi, MD PhD

Blood (2019) 134 (Supplement_1): 459.

https://doi.org/10.1182/blood-2019-124587

Published: 2019

Journal Articles

Occurrence and Resolution of Anthracycline Cardiotoxicity and Impact on Treatment Outcomes Among Children Treated on the AAML1031 Clinical Trial: A Report from the Children's Oncology Group

Kelly D Getz, Lillian Sung, MD PhD, Robert B. Gerbing, Todd A. Alonzo, PhD, Yimei Li, PhD, Yuan-Shung V. Huang, MS, Kasey J Leger, MD MSc, Jessica A. Pollard, MD, Todd M Cooper, DO, Edward Anders Kolb, MD, Alan S Gamis, MD MPH, Richard Aplenc, MD PhD

Blood (2019) 134 (Supplement_1): 331.

https://doi.org/10.1182/blood-2019-131227

Published: 2019

Journal Articles

Somatic Bzip Mutations of CEBPA Are Associated with Favorable Outcome Regardless of Presence As Single Vs. Double Mutation

Katherine Tarlock, MD, Todd A. Alonzo, PhD, Yi-Cheng Wang, Robert B. Gerbing, Rhonda E. Ries, MA, Tiffany A. Hylkema, BS, William G. Woods, MD, Todd M Cooper, DO, Alan S Gamis, MD MPH, Richard Aplenc, MD PhD, Soheil Meshinchi, MD PhD

Blood (2019) 134 (Supplement_1): 181.

https://doi.org/10.1182/blood-2019-126273

Published: 2019

Journal Articles

A Phase 1/2 Study of Quizartinib (Q) in Combination with Re-Induction Chemotherapy and As Single-Agent Continuation Therapy in Pediatric and Young Adult Patients with Relapsed/Refractory (R/R) FLT3 -ITD Acute Myeloid Leukemia (AML)

C. Michel Zwaan, MD PhD, Edward Anders Kolb, MD, Derek E. Mires, PharmD, Michele Vigliotti, PharmD, Jingdong Xie, PhD, Pamela Downs, BS, Arthur P DeCillis, MD MS, Cara A Rabik, MD PhD, Todd M Cooper, DO

Blood (2019) 134 (Supplement_1): 3937.

https://doi.org/10.1182/blood-2019-121736

Published: 2019

Journal Articles

Safety, Efficacy, and PK of the BCL2 Inhibitor Venetoclax in Combination with Chemotherapy in Pediatric and Young Adult Patients with Relapsed/Refractory Acute Myeloid Leukemia and Acute Lymphoblastic Leukemia: Phase 1 Study

Seth E Karol, MD, Todd M Cooper, DO, Henrique Bittencourt, Lia Gore, MD, Maureen M O'Brien, MD, Christopher Fraser, MD, Marion Gambart, MD, Gunnar Cario, MD PhD, Christian Michel Zwaan, MD PhD, Jean-Pierre Bourquin, MD PhD, Mignon L. Loh, MD, Hubert Caron, MD PhD, Betty Prine, Ahmed Hamed Salem, PhD FCP, Kristina Unnebrink, Bo Tong, PhD, Tammy Palenski, PhD, Andrew E. Place, MD PhD

Blood (2019) 134 (Supplement_1): 2649.

https://doi.org/10.1182/blood-2019-129805

Published: 2019

Journal Articles

Matched Targeted Therapy for Pediatric Patients with Relapsed, Refractory or High-Risk Leukemias: A Report from the LEAP Consortium

Blood (2018) 132 (Supplement 1): 261.

https://doi.org/10.1182/blood-2018-99-116948

Published: 2018

Journal Articles

Use of Gemtuzumab Ozogamicin for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia (AML) or Acute Promyelocytic Leukemia (APL) in an Expanded Access Setting at Our Cancer Consortium

Blood (2018) 132 (Supplement 1): 2710.

https://doi.org/10.1182/blood-2018-99-116908

Published: 2018

Journal Articles

Phase I Study of the Selinexor in Relapsed/Refractory Childhood Acute Leukemia

Andrew E. Place, MD PhD, Traci M. Blonquist, MS, Elliot Stieglitz, MD, Todd M Cooper, DO, Lia Gore, MD, Richard Aplenc, MD PhD, Mignon L. Loh, MD, Melinda Pauly, MD, Rachel E. Rau, MD, Michael J. Burke, MD, Julia Etchin, PhD, A. Thomas Look, MD, Maria Luisa Sulis, MD, Lewis B. Silverman, MD

Blood (2018) 132 (Supplement 1): 1405.

https://doi.org/10.1182/blood-2018-99-116689

Published: 2018

Journal Articles

Enhancement of Eligibility Guidelines for Gemtuzumab Ozogamicin Therapy for Childhood Acute Myeloid Leukemia: A Report from Children's Oncology Group Protocol AAML0531

Laura Pardo, Lisa Eidenschink Brodersen, PhD, Jatinder K Lamba, PhD, Todd A Alonzo, PhD, Yi-Cheng Wang, Dana Paine, Alan S Gamis, MD MPH, E. Anders Kolb, MD, Jessica A. Pollard, MD, Todd M Cooper, DO, Richard Aplenc, MD PhD, Soheil Meshinchi, MD PhD, Michael R. Loken, PhD

Blood (2018) 132 (Supplement 1): 1490.

https://doi.org/10.1182/blood-2018-99-115053

Published: 2018

Journal Articles

Revised Risk Stratification Criteria for Children with Newly Diagnosed Acute Myeloid Leukemia: A Report from the Children's Oncology Group

Todd M Cooper, DO, Rhonda E. Ries, MA, Todd A Alonzo, PhD, Robert B Gerbing, Michael R. Loken, PhD, Lisa E. Brodersen, PhD, Susana C. Raimondi, PhD, Betsy A Hirsch, PhD, Richard Aplenc, MD, Alan S Gamis, MD MPH, Edward A Kolb, MD, Soheil Meshinchi, MD PhD

Blood (2017) 130 (Supplement 1): 407.

https://doi.org/10.1182/blood.V130.Suppl_1.407.407

Published: 2017

NARROW

Pediatric Patients with Relapsed/Refractory Acute Lymphoblastic Leukemia Harboring Heterogeneous Genomic Profiles Respond to Venetoclax in Combination with Chemotherapy

CPX-351 Population Pharmacokinetics in Pediatric and Adult Patients with Acute Myeloid Leukemia (AML)

CPX-351 Exposure-Response Analyses for Efficacy and Safety in Pediatric Patients with Relapsed or Refractory Acute Myeloid Leukemia (AML)

Venetoclax Crosses the Blood Brain Barrier: A Pharmacokinetic Analysis of the Cerebrospinal Fluid in Pediatric Leukemia Patients

Integrated Stem Cell Signature and Cytomolecular Risk Determination in Pediatric Acute Myeloid Leukemia

Venetoclax Alone or in Combination with Chemotherapy: Responses in Pediatric Patients with Relapsed/Refractory Acute Myeloid Leukemia with Heterogeneous Genomic Profiles

The Molecular Characteristics and Clinical Relevance of NUP98 -Other Translocations in Pediatric Acute Myeloid Leukemia

Characteristics and Prognostic Effects of IDH Mutations across the Age Spectrum in AML: A Collaborative Analysis from COG, SWOG, and ECOG

Newly Diagnosed Childhood AML Patients Treated with Bortezomib Show Superior Survival If CD74 Is Expressed: A Report of 991 Patients from the Children's Oncology Group AAML1031 Protocol

Structural Variants Involving MLLT10/AF10 Are Associated with Adverse Outcome in AML Regardless of the Partner Gene - a COG/Tpaml Study

Correlation of CD123 Expression Level with Disease Characteristics and Outcomes in Pediatric Acute Myeloid Leukemia: A Report from the Children's Oncology Group

Occurrence and Resolution of Anthracycline Cardiotoxicity and Impact on Treatment Outcomes Among Children Treated on the AAML1031 Clinical Trial: A Report from the Children's Oncology Group

Somatic Bzip Mutations of CEBPA Are Associated with Favorable Outcome Regardless of Presence As Single Vs. Double Mutation

A Phase 1/2 Study of Quizartinib (Q) in Combination with Re-Induction Chemotherapy and As Single-Agent Continuation Therapy in Pediatric and Young Adult Patients with Relapsed/Refractory (R/R) FLT3 -ITD Acute Myeloid Leukemia (AML)

Safety, Efficacy, and PK of the BCL2 Inhibitor Venetoclax in Combination with Chemotherapy in Pediatric and Young Adult Patients with Relapsed/Refractory Acute Myeloid Leukemia and Acute Lymphoblastic Leukemia: Phase 1 Study

Matched Targeted Therapy for Pediatric Patients with Relapsed, Refractory or High-Risk Leukemias: A Report from the LEAP Consortium

Use of Gemtuzumab Ozogamicin for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia (AML) or Acute Promyelocytic Leukemia (APL) in an Expanded Access Setting at Our Cancer Consortium

Phase I Study of the Selinexor in Relapsed/Refractory Childhood Acute Leukemia

Enhancement of Eligibility Guidelines for Gemtuzumab Ozogamicin Therapy for Childhood Acute Myeloid Leukemia: A Report from Children's Oncology Group Protocol AAML0531

Revised Risk Stratification Criteria for Children with Newly Diagnosed Acute Myeloid Leukemia: A Report from the Children's Oncology Group

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only